Fondaparinux in Critically Ill Patients With Renal Failure
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether a dose-adjusted prophylaxis
fondaparinux regimen of 2.5 milligrams (mg) subcutaneously administered every (q) 48 hours
(hr) in patients with renal failure achieves peak and trough levels similar to patients with
normal renal function, and protects patients from developing venous thromboembolism (VTE).
Our hypothesis is that a dose-adjusted fondaparinux regimen, which extends the dosing
interval from q24 to q48 hr, in patients with estimated creatinine clearance of < 30 ml/min,
will be safe and effective.